Compare ANEB & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANEB | PMN |
|---|---|---|
| Founded | 2020 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.8M | 23.5M |
| IPO Year | 2021 | N/A |
| Metric | ANEB | PMN |
|---|---|---|
| Price | $1.16 | $8.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $72.67 |
| AVG Volume (30 Days) | ★ 103.1K | 33.1K |
| Earning Date | 02-13-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $6.27 |
| 52 Week High | $3.42 | $39.75 |
| Indicator | ANEB | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 19.72 | 70.99 |
| Support Level | $1.14 | $8.00 |
| Resistance Level | $2.40 | $9.15 |
| Average True Range (ATR) | 0.19 | 0.58 |
| MACD | -0.11 | -0.26 |
| Stochastic Oscillator | 4.77 | 44.44 |
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.